newsfilter
← Latest News
GlobeNewswire·

Hepion Pharmaceuticals Announces Publication of Phase 2a 'AMBITION' Clinical Trial Results

- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic effects with longer treatment duration - - Enrollment initiated in Phase 2b